PNPLA3

Across TCGA pan-cancer cohorts, PNPLA3 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated PNPLA3 data layer compared with 3 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher PNPLA3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PNPLA3 expression acts as an unfavorable survival marker, although some lineages such as SCLC and READ show a favorable association.

MESO, ACC, and THCA are the cancer types where PNPLA3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.246	0.520	<.001	105	view →
ACC	DFS	Median	All	0.287	0.615	<.001	101	view →
THCA	OS	Median	II,III,IV	0.905	0.991	.001	62	view →
SCLC	OS	Quartile	All	0.703	0.302	<.001	49	view →
BLCA	DFS	Tertile	II,III,IV	0.453	0.622	.003	37	view →
BRCA	DFS	Median	IV	0.440	0.953	<.001	36	view →
SKCM	DFS	Tertile	II,III,IV	0.474	0.709	.003	32	view →
READ	OS	Tertile	II,III,IV	0.874	0.477	.013	31	view →
ESCA	OS	Tertile	All	0.785	0.541	.001	24	view →
HNSC	OS	Tertile	IV	0.806	0.617	.005	24	view →
SARC	OS	Tertile	All	0.629	0.810	.001	20	view →
DLBC	DFS	Quartile	III,IV	1.000	0.310	.040	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

PNPLA3–MESO (OS)

Open the MESO breakdown →